Sotac Pharmaceuticals AGM votes and auditors
NSE: SOTACPharmaceuticals & Biotechnology
Share price at the NSE close on 30 Oct 2026. Previous close ₹106.35.
30 Oct: open ₹111.65, high ₹111.65, low ₹111.65
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹123 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.39
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,200100.0% delivered
Sotac Pharmaceuticals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s Keyur Shah & Co.Peer-review certificate valid to Dec 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Sotac Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Sotac Pharmaceuticals dividend history
Annual general meeting, 30 Sep 2026
231 shareholders on the register on 23 Sep 2026; present: 5 promoters and 5 others; votes counted by Ms. Anjali Sangtani / SCS and Co. LLP.
Adoptionof Audited Financial Statements: To receive, consider and adopt; a) The Audited Standalone Financial Statement of the Company for the Financial Year ended on March 31, 2026 and the report of the Board of Directors and Auditors thereon; and b) The Audited Consolidated Financial Statement of the Company for the Financial Year ended on March 31, 2026 and the report of Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.69% · promoters 100.00% · institutions 0.00% · other public 17.17%
- To appoint a director in place of Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252), who retires by rotation and being eligible, offers himself for re-appointmentOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.69% · promoters 100.00% · institutions 0.00% · other public 17.17%
- To declare final dividend of Rs. 0.20/- (Twenty paisa only) per Equity share of face value Rs.10/- each (i.e. 2% of face value) for the financial year ended on March 31, 2026Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.69% · promoters 100.00% · institutions 0.00% · other public 17.17%
- To ratify the remuneration payable to M/s. Suthar Haresh & Associates, Cost Accountants (FRN.: 002124) Cost Auditor of the Company for the Financial Year ended on March 31, 2027Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.69% · promoters 100.00% · institutions 0.00% · other public 17.17%
- Approval of material related party transactions with subsidiary company “SOTAC HEALTHCARE PRIVATE LIMITED”OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 1.84% · promoters 0.00% · institutions 0.00% · other public 17.17%
- Approval of material related party transactions with subsidiary company “SOTAC LIFESCIENCES PRIVATE LIMITED”OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 1.84% · promoters 0.00% · institutions 0.00% · other public 17.17%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
The company's results filing for the quarter to Mar 2026 says no statement of how money raised was used applies to it.